BioPharmSignal logoBioPharmSignal

Biotech News

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Protara Therapeutics (TARA)Protara TherapeuticsEarnings

The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion leader (KOL) perspectives on May 19, 2026 at 4:30 pm ET Interim safety and durability data from

Related news

TARAProtara Therapeutics2026-08-11 12:00 EST

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

KYMRKymera2026-08-05 11:00 EST

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

KYMRKymera2026-07-28 20:01 EST

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

View all latest news

Protara Therapeutics

Cancer and Rare-Disease Company Protara Therapeutics develops therapies for cancer and rare diseases, with programs spanning cell-based immunopotentiation and phospholipid substrate replacement. Bladder Cancer The ADVANCED program evaluates intravesical TARA-002 in high-grade non-muscle-invasive bladder cancer across BCG-unresponsive,...

Recent company news

TARAProtara Therapeutics2026-09-08 20:05 EST

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

TARAProtara Therapeutics2026-08-11 12:00 EST

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

TARAProtara Therapeutics2026-05-20 12:00 EST

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

TARAProtara Therapeutics2026-05-18 12:00 EST

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

TARAProtara Therapeutics2026-05-15 11:00 EST

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

Stock data

Close
3.55 USD
Market cap
243.93M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States